EBS Q3 2024 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$294M+8.6% YoY

Gross Profit

$164M55.9% margin

Operating Income

$65M22.0% margin

Net Income

$115M39.1% margin

EPS (Diluted)

$2.06

QoQ Revenue Growth

+15.4%

Cash Flow

Operating Cash Flow

$154M

Free Cash Flow

$148M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$969M

Stockholders' Equity

$508M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$294M	$271M	+8.6%
Gross Profit	$164M	$92M	+77.7%
Operating Income	$65M	-$242M	+126.6%
Net Income	$115M	-$263M	+143.6%

Revenue Segments

Product

$270M92%

Contract Development And Manufacturing

$14M5%

Contracts and Grants

$10M3%

Geographic Segments

Services Segment

$14M100%